Kimberly Rath, PharmD, is a freelance health writer who previously worked as a clinical pharmacist with Elevance Health for a decade. She has also worked for Amerigroup and Sentara Group.
Study Explores Radiation-Free Transplant Approach for Patients With Dyskeratosis Congenita
November 8th 2024A new study finds that eliminating radiation from conditioning regimens in patients with dyskeratosis congenita undergoing allogeneic hematopoietic cell transplantation did not negatively affect survival or increase complications.
Enhancing Myasthenia Gravis Care With AI-Powered Telemedicine
November 8th 2024Researchers introduce a telemedicine system powered by artificial intelligence (AI) that automatically scores neuromuscular examinations, offering the potential to enhance patient monitoring, reduce variability in clinical trials, and improve access to care for neuromuscular disorders like myasthenia gravis.
CNS-Directed AAV Gene Therapy: Immune Dynamics and Clinical Implications
October 17th 2024A new study reviews how various routes of adeno-associated virus (AAV) gene therapy administration influence local and peripheral immune responses, with a focus on those observed in clinical trials targeting the central nervous system (CNS).
New Study Further Illuminates PARP1 Expression in ALL, AML, CML With BCR::ABL1 p190+
October 3rd 2024Researchers investigate the expression of PARP1 in leukemias with BCR::ABL1 p190+ translocation, finding differential expression in ALL, AML, and CML but no significant correlation with clinical parameters.
Multidisciplinary Prehabilitation to Boost Outcomes in AML, MDS for Stem Cell Transplant
September 20th 2024A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) offered an allogenic hematopoietic stem cell transplantation.
Acalabrutinib vs Ibrutinib: Real-World Insights Into Safety Differences for Patients With CLL
September 12th 2024The latest study findings suggest that acalabrutinib may be a safer option than ibrutinib for patients with chronic lymphocytic leukemia, offering a lower risk of serious cardiovascular and infection-related adverse events.
B-Cell Activating Factor Levels May Predict Reduced Risk of CLL, Study Finds
September 4th 2024A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential biomarkers for assessing CLL risk.
Novel CAR-E Platform Enhances CAR T-Cell Functionality in Cancer Treatment
August 16th 2024Researchers introduce a chimeric antigen receptor–enhancer (CAR-E) therapeutic platform that significantly extends the effectiveness and memory of CAR T cells, potentially preventing relapse in patients who have cancer.